TransCode Therapeutics Inc. - חוב לטווח קצר של החברה RNAZ
TransCode Therapeutics (RNAZ) specializes in oncology treatment via RNA therapy, leveraging the development of the TTX-MS138 delivery system and the pursuit of strategic partners. High costs associated with clinical trials and patent protection create a significant barrier to entry for new players. The price indicator on the GURU.Markets platform chart, where the metric reached 0.00, complements data regarding the implementation of AI and robotics to automate drug synthesis.
%3A%20%D7%94%D7%9C%D7%95%D7%95%D7%90%D7%95%D7%AA%20%D7%95%D7%90%D7%A9%D7%A8%D7%90%D7%99%20%D7%9C%D7%98%D7%95%D7%95%D7%97%20%D7%A7%D7%A6%D7%A8%20%D7%A9%D7%9C%20%D7%94%D7%97%D7%91%D7%A8%D7%94&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_RNAZ_-_TransCode-Therapeutics_-_Company-Short-Term-Loans-and-Borrowings "RNAZ TransCode Therapeutics Inc.: חובות לטווח קצר של החברה בטווח 04.07.2022 - 28.10.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור TransCode Therapeutics Inc. (RNAZ)
TransCode Therapeutics (RNAZ) is engaged in the capital-intensive development of RNA-based drugs, where intensive clinical trial expenditures place a significant strain on liquidity. This metric aggregates all obligations maturing within one year, allowing investors to assess default risk amid a high cash burn rate, which makes the analysis of current liability trends critical for forecasting the company's financial stability.